Stacey GandlerBrand Nourishment
Matthew DurhamOmnidynamic Marketing
Liz KaneImpactful Strategy
Suma Ramadas, PhDMedical Affairs
Frank BurrellScientific Storytelling
Brenda SnowAuthentic Patient Voice
David LinetskyPoint-of-Care Marketing
Joey CohenMedication Adherence
Paul TheisenPatient Acquisition
Daniel SontupeMarket Access
Amy GilesIncreasing Engagement
Matt TurnerPatient Affordability
Bud BilanichSuccess Coach
Pat PurcellMeeting Engagement
YELIVA®, a proprietary, first-in-class SK2 inhibitor, was granted FDA Orphan Drug designation for the ...
Username
Email
Password
Confirm Password
Remember Me
Username or Email
